Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein
The Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating TNFRSF10B/DR5/TRAIL-R2/CD262 function and its implications in health and disease.
This product (SKU: RPCB0398) is produced using HEK293 cells and features a C-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 15.13 kDa with an observed molecular weight of 17 kDa under denaturing conditions, achieving ≥ 90 % as determined by SDS-PAGE.. Functional bioactivity has been validated through rigorous quality control assays, confirming its suitability for demanding research applications.
Key Features
High Purity by Affinity Chromatography
Mammalian & Bacterial Expression Systems
High lot-to-lot consistency via strict QC
Product Name:
Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein
High quality, high purity and low endotoxin recombinant Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein (RPCB0398), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 0.1 EU/μg of the protein by LAL method.
Purity:
≥ 90 % as determined by SDS-PAGE.
Formulation:
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.
Bio-Activity:
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human TRAIL at 2 μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED 50 for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.
Measured by its binding ability in a functional ELISA.Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.
Reconstitution:
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
This protein is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.
Immobilized Recombinant Human TRAIL at 2μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.
Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.
